Abstract
This review summarizes recent progress in understanding the role of p53-upregulated mediator of apoptosis (PUMA) in molecular pathways with respect to its potential therapeutic applications. Particular emphasis is given to the PUMA´s role in ionizing radiation-induced signalling as radiotoxicity of normal tissue is mediated mostly via apoptosis. PUMA and its p53-dependent and p53- independent induction are described and potential use as a new target for the development of radioprotective agents is suggested. Further implications, including targeting PUMA to prevent and treat cardiovascular and neurodegenerative diseases, are also discussed together with an overview of other therapeutic applications. Finally, basic chemical structures for the development of novel PUMA modulators such as pifithrine derivatives, kinase inhibitors or modulators of Bcl-2 protein family are described.
Keywords: PUMA, ionizing radiation, small molecule inhibitor, radioprotection, hearth, brain.
Current Drug Targets
Title:New Light on An Old Friend: Targeting PUMA in Radioprotection and Therapy of Cardiovascular and Neurodegenerative Diseases
Volume: 19 Issue: 16
Author(s): Ales Tichy, Jan Marek, Radim Havelek*, Jaroslav Pejchal, Martina Seifrtova, Lenka Zarybnicka, Alzbeta Filipova, Martina Rezacova and Zuzana Sinkorova
Affiliation:
- Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove,Czech Republic
Keywords: PUMA, ionizing radiation, small molecule inhibitor, radioprotection, hearth, brain.
Abstract: This review summarizes recent progress in understanding the role of p53-upregulated mediator of apoptosis (PUMA) in molecular pathways with respect to its potential therapeutic applications. Particular emphasis is given to the PUMA´s role in ionizing radiation-induced signalling as radiotoxicity of normal tissue is mediated mostly via apoptosis. PUMA and its p53-dependent and p53- independent induction are described and potential use as a new target for the development of radioprotective agents is suggested. Further implications, including targeting PUMA to prevent and treat cardiovascular and neurodegenerative diseases, are also discussed together with an overview of other therapeutic applications. Finally, basic chemical structures for the development of novel PUMA modulators such as pifithrine derivatives, kinase inhibitors or modulators of Bcl-2 protein family are described.
Export Options
About this article
Cite this article as:
Tichy Ales , Marek Jan, Havelek Radim *, Pejchal Jaroslav , Seifrtova Martina , Zarybnicka Lenka , Filipova Alzbeta , Rezacova Martina and Sinkorova Zuzana , New Light on An Old Friend: Targeting PUMA in Radioprotection and Therapy of Cardiovascular and Neurodegenerative Diseases, Current Drug Targets 2018; 19 (16) . https://dx.doi.org/10.2174/1389450119666180406110743
DOI https://dx.doi.org/10.2174/1389450119666180406110743 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Damage Repair and Response Proteins as Targets for Cancer Therapy
Current Medicinal Chemistry Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism MicroRNAs as Main Players in the Pathogenesis of Chronic Lymphocytic Leukemia
MicroRNA STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry Current Immunotherapies for Renal Cell Carcinoma
Current Molecular Pharmacology Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells
Current Signal Transduction Therapy Akt Pathway Inhibitors
Current Topics in Medicinal Chemistry Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy Controversies in the Use of Nutritional Supplements in Ophthalmology
Current Pharmaceutical Design Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Anticancer Agents: VTA or VDA
Current Bioactive Compounds P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update
Current Drug Metabolism Erythropoietin in Cancer: An Update
Current Molecular Medicine Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued)